WRBY
Premium GrowerWarby Parker Inc. · Healthcare · United States · $3.2B cap · $115.3M/day traded
$30.15 +0.8% · close 11 Nov · scored 11 Nov
Score up 1.5 since 10 Nov.
Premium Grower: Strong business with the market behind it, priced at a premium.
Around its 5 Nov results, analysts raised next year's EPS estimate 3.3%.
As of 11 Nov 2026, the MoatMap Score for Warby Parker Inc. (WRBY) is 54/100, ranked against 25,000+ stocks in 38 markets (Quality 59, Value 13, Momentum 76, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT WARBY PARKER INC.
Read
Warby Parker Inc. is a vertically integrated, omni-channel eyewear brand that designs and sells prescription glasses, sunglasses, and contact lenses, while also providing eye exams. The company's competitive moat is built on its direct-to-consumer model, which bypasses traditional optical licensing giants to offer premium products at accessible price points. It operates as a disruptive consumer brand leveraging a highly productive physical retail expansion strategy.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 598.1M | 669.8M | 771.3M | 871.9M | 13.4% | 934.7M | 971.1M | 1.2B | 16.2% |
| EPS | -0.96 | -0.54 | -0.17 | 0.01 | — | 0.06 | — | — | — |
| Shares | 115.3M | 118.2M | 120.8M | 122.4M | +6.2% | 108.8M | — | — | — |
| Debt | 173.4M | 174.5M | 225.4M | 233.1M | 10.4% | 264.8M | — | — | — |
| Equity | 286.6M | 301.8M | 340.1M | 367.7M | 8.7% | — | — | — | — |
| Op CF | 10.4M | 61.0M | 98.7M | 110.8M | 120.2% | 102.1M | — | — | — |
| Inv CF | -60.2M | -54.7M | -66.0M | -67.0M | — | — | — | — | — |
| Fin CF | 3.3M | 2.9M | 5.0M | -12.0M | — | — | — | — | — |
No clear trend: not near its 52-week low, and not in a steady uptrend.
Swung more than 89% of stocks we rank over the past year (volatility 82% a year).
How this is worked out
The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of WRBY are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| WRBY | Warby Parker Inc.(you) | $3.2B | 54 |
| ATRC | AtriCure, Inc. | $3.0B | 61 |
| XRAY | DENTSPLY SIRONA Inc. | $1.9B | 51 |
| LMAT | LeMaitre Vascular, Inc. | $1.9B | 50 |
| MMED | MiniMed Group, Inc. | $5.2B | 59 |
| AZTA | Azenta, Inc. | $1.6B | 45 |
| TFX | Teleflex Incorporated | $5.8B | 65 |
| ICUI | ICU Medical, Inc. | $4.2B | 72 |
| RGEN | Repligen Corporation | $11.2B | 53 |
| PLSE | Pulse Biosciences, Inc. | $3.8B | 28 |
Peer medians: ROE -31.0% · P/E 25.7x · Gross margin 63.3%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.